(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 August 2010 (19.08.2010)

PCT

(10) International Publication Number
WO 2010/093944 A3

(51) International Patent Classification:
A61K 9/16 (2006.01)

(21) International Application Number:
PCT/US2010/024127

(22) International Filing Date:
12 February 2010 (12.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/152,608 13 February 2009 (13.02.2009) US

(71) Applicant *(for all designated States except US)*: **REATA PHARMACEUTICALS, INC.** [US/US]; 2801 Gateway Drive Suite 150, Irving, Texas 75063-2648 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ZHANG, Jiang** [CN/US]; 715 Hawk Lane, Coppell, Texas 75019 (US). **MEYER, Colin J.** [US/US]; 3884 Truman Drive, Frisco, Texas 75034 (US).

(74) Agents: **BENT, Stephen A.** et al.; FOLEY & LARDNER LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,

[Continued on next page]

(54) Title: DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME

Figure 1





Figure 2



(57) Abstract: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.

WO 2010/093944 A3

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
11 August 2011